Iskeleli G, Bilgeç MD, Arici C, Atalay E, Ogreden T, Aydin A. Richner-Hanhart syndrome (tyrosinemia type II): a case report of delayed diagnosis with pseudodendritic corneal lesion. Turk J Pediatr. 2011 Nov-Dec. 53(6):692-4. [Medline].
Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet. 2001 Aug 15. 10(17):1741-52. [Medline].
Bliksrud YT, Ellingsen A, Bjørås M. Fumarylacetoacetate inhibits the initial step of the base excision repair pathway: implication for the pathogenesis of tyrosinemia type I. J Inherit Metab Dis. 2013 Sep. 36(5):773-8. [Medline].
Li L, Zhang Q, Yang H, Zou Q, Lai C, Jiang F, et al. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1. J Biol Chem. 2017 Mar 17. 292 (11):4755-4763. [Medline].
Maiorana A, Malamisura M, Emma F, et al. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type I. Mol Genet Metab. November 2014. 113:188-193. [Medline].
Larochelle J, Alvarez F, Bussières JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab. 2012 Sep. 107(1-2):49-54. [Medline].
Thimm E, Richter-Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2012 Mar. 35(2):263-8. [Medline].
McKiernan PJ, Preece MA, Chakrapani A. Outcome of children with hereditary tyrosinemia following newborn screening. Arch Dis Child. August 2015. 100:738-741. [Medline].
van Ginkel WG, Jahja R, Huijbregts SC, Daly A, MacDonald A, De Laet C, et al. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet J Rare Dis. 2016 Jun 29. 11 (1):87. [Medline].
García MI, de la Parra A, Arias C, Arredondo M, Cabello JF. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet. Mol Genet Metab Rep. 2017 Jun. 11:12-16. [Medline].
Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis. 2012 Mar 29. [Medline].
Angeleri F, Bergeron A, Morrow, G, et al. Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type I. JIMD Rep. 2015. 19:43-58. [Medline].
Malik S, NiMhurchadha S, Jackson C, et al. Treatment adherence in type I hereditary tyrosinemia(HT1): a mixed-method investigation into the beliefs, attitudes and behavior of adolescent patients, their families and health-care team. JIMD Rep. 2015. 18:13-22. [Medline].
Koelink CJ, van Hasselt P, van der Ploeg A, et al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?. Mol Genet Metab. 2006 Dec. 89(4):310-5. [Medline].
Sniderman King L, Trahms C, Scott CR. Tyrosinemia type I(Internet). Gene Reviews{Internet}. July 2014. [Medline]. [Full Text].
de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013 Jan 11. 8:8. [Medline]. [Full Text].
[Guideline] Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005 Jun. 41(6):1407-32. [Medline].
Nitisinone: new drug. Type 1 tyrosinemia: an effective drug. Prescrire Int. 2007 Apr. 16(88):56-8. [Medline].
Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type I. J Inherit Metab Dis. 2012 Feb 4. [Medline].
Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008 Jun. 31(3):399-402. [Medline].
Santra S, Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May. 9(7):1229-36. [Medline].
Bendadi F, de Koning TJ, Visser G, et al. Impaired Cognitive Functioning in Patients with Tyrosinemia Type I Receiving Nitisinone. J Pediatr. 2013 Nov 14. [Medline].
Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol. Aug 2002. 134(2):266-8. [Medline].
Ashorn M, Pitkanen S, Salo MK, Heikinheimo M. Current strategies for the treatment of hereditary tyrosinemia type I. Paediatr Drugs. 2006. 8(1):47-54. [Medline].
Barkaoui E, Debray D, Habes D, et al. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I]. Arch Pediatr. May 1999. 6(5):540-4. [Medline].
Berger R, Smit GP, Stoker-de Vries SA, Duran M, Ketting D, Wadman SK. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Clin Chim Acta. 1981 Jul 18. 114(1):37-44. [Medline].
Bijarnia S, Puri RD, Ruel J, et al. Tyrosinemia type I--diagnostic issues and prenatal diagnosis. Indian J Pediatr. 2006 Feb. 73(2):163-5. [Medline].
Bruneau N, St-Vil D, Luks FI, et al. [Surgical and metabolic aspects of liver transplantation for tyrosinemia]. Ann Chir. 1993. 47(9):803-9. [Medline].
Crone J, Moslinger D, Bodamer OA, et al. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I. Acta Paediatr. 2003 May. 92(5):625-8. [Medline].
Endo F, Sun MS. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J Inherit Metab Dis. 2002 May. 25(3):227-34. [Medline].
Fisch RO, McCabe ER, Doeden D, et al. Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia. J Pediatr. 1978 Oct. 93(4):592-6. [Medline].
Gartner JC Jr, Zitelli BJ, Malatack JJ, et al. Orthotopic liver transplantation in children: two-year experience with 47 patients. Pediatrics. 1984 Jul. 74(1):140-5. [Medline].
Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J. Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. J Pediatr Gastroenterol Nutr. 2002 Jul. 35(1):73-8. [Medline].
Heath SK, Gray RG, McKiernan P, et al. Mutation screening for tyrosinaemia type I. J Inherit Metab Dis. 2002 Oct. 25(6):523-4. [Medline].
Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis. Aug 1998. 21(5):507-17. [Medline].
Hostetter MK, Levy HL, Winter HS, Knight GJ, Haddow JE. Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia. N Engl J Med. 1983 May 26. 308(21):1265-7. [Medline].
Kvittingen EA, Jellum E, Stokke O. Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta. 1981 Sep. 115(3):311-9. [Medline].
Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A. Oct 1977. 74(10):4641-5. [Medline].
Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4- hydroxyphenylpyruvate dioxygenase. Lancet. Oct 3 1992. 340(8823):813-7. [Medline].
Luijerink MC, Jacobs SM, van Beurden EA, et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol. 2003 Dec. 39(6):901-9. [Medline].
Magera MJ, Gunawardena ND, Hahn SH, et al. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Mol Genet Metab. 2006 May. 88(1):16-21. [Medline].
McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinemia type I. Drugs. 2006. 66(6):743-50. [Medline].
Roth KS, Spencer PD, Higgins ES, Spencer RF. Effects of succinylacetone on methyl alpha-D-glucoside uptake by the rat renal tubule. Biochim Biophys Acta. 1985 Oct 24. 820(1):140-6. [Medline].
Russo P, O'Regan S. Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet. 1990 Aug. 47(2):317-24. [Medline].
Scott CR. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet. 2006 May 15. 142(2):121-6. [Medline].
Spencer PD, Roth KS. Effects of succinylacetone on amino acid uptake in the rat kidney. Biochem Med Metab Biol. 1987 Feb. 37(1):101-9. [Medline].
Wyss PA, Boynton SB, Chu J, Spencer RF, Roth KS. Physiological basis for an animal model of the renal Fanconi syndrome: use of succinylacetone in the rat. Clin Sci (Lond). 1992 Jul. 83(1):81-7. [Medline].